Hypoxia Preconditioning Increases Adipose Stem Cell Fusion Mass in Rats

Optimizing Biological Adjuncts in Lumbar Arthrodesis

Lumbar degenerative disc disease and associated low back pain represent a massive clinical burden, frequently requiring surgical fusion when conservative measures prove inadequate [1]. The success of these procedures depends heavily on the biological environment of the fusion site, where complex signaling pathways and mechanical factors dictate the rate of bone remodeling [2]. While autologous bone remains the gold standard, the search for effective biological adjuncts has led to the investigation of mesenchymal stem cells due to their multipotent differentiation and immunomodulatory properties [3]. Despite their potential, the clinical application of cell-based therapies is often limited by poor graft survival and the lack of standardized protocols for optimizing cell performance in ischemic tissue [4, 5]. A study using a rat model now investigates a method to enhance the resilience of adipose-derived cells before implantation by pharmacologically simulating a low-oxygen environment.

Overcoming Ischemic Limitations in Stem Cell Grafting

Adipose-derived stem cells (ADSCs) offer a practical alternative to bone marrow-derived stem cells, primarily due to their relative abundance and the reduced morbidity associated with their harvest. However, the clinical utility of these multipotent cells in spinal surgery is frequently compromised by the harsh conditions of the graft recipient site. Specifically, ADSCs are often limited by poor cell survival following implantation into the hypoxic environment surrounding the fusion site, where low oxygen tension can lead to significant cell death before the graft can successfully integrate and initiate osteogenesis (the process of new bone formation). To address this metabolic challenge, the researchers utilized dimethyloxalylglycine (DMOG), a small molecule that acts as a stabilizer of hypoxia-inducible factor-1α. This protein serves as a master regulator of the cellular response to low oxygen, and its stabilization allows cells to adapt to ischemic stress by upregulating protective pathways. Previous data indicate that DMOG has been shown to boost both osteogenic and angiogenic (blood vessel-forming) functions of mesenchymal stem cells under low oxygen conditions. By pharmacologically mimicking a low-oxygen state, DMOG prepares the cells for the physiological rigors of the post-implantation environment, potentially increasing the number of viable cells available to contribute to the fusion mass. The study investigated whether preconditioning ADSCs with DMOG and hypoxia could improve their bone-forming capacity and stimulate vascularization in a rat model of L4-L5 posterolateral spinal fusion. The researchers harvested ADSCs from the inguinal fat pads of Lewis rats aged 6 to 8 weeks and expanded them in culture. By treating passage 1 cells (the first generation of cells after the initial harvest) at 80 percent confluency with 1 ng of DMOG for 24 hours, the team sought to enhance the biological performance of the 2 million cells subsequently seeded onto each Vitoss scaffold. This experimental design aimed to determine if metabolic priming could overcome the high mortality rates typically seen in cell-based spinal fusion adjuncts.

Experimental Design and Preconditioning Protocol

The researchers utilized a standardized animal model to evaluate the efficacy of metabolic preconditioning in spinal arthrodesis. Adipose-derived stem cells were harvested from the inguinal fat pads of Lewis rats aged 6 to 8 weeks. These cells were selected for their high proliferative capacity and relative ease of isolation compared to bone marrow sources. Following harvest, the cells underwent culture expansion to reach the necessary concentrations for therapeutic application. The preconditioning protocol focused on stabilizing hypoxia-inducible factor-1α during the early stages of cell culture. Once the adipose-derived stem cells reached 80 percent confluency at passage 1, they were exposed to 1 ng of DMOG for a duration of 24 hours. This specific concentration and timing were designed to prime the cells' metabolic pathways for the low-oxygen environment of the surgical site. For the surgical intervention, the researchers expanded the cells to passage 2 (the second generation of subcultured cells) and seeded 2 million passage 2 cells onto each Vitoss scaffold, a synthetic bone graft substitute composed of beta-tricalcium phosphate. The experimental subjects underwent L4-L5 posterolateral spinal fusion, a procedure that mimics the clinical challenges of achieving solid bony union in human lumbar surgery. To isolate the effect of the hypoxia-mimetic treatment, the rats were randomly assigned to one of two experimental groups. The first group received the Vitoss scaffold containing DMOG-preconditioned passage 2 adipose-derived stem cells, while the control group received the same scaffold seeded with nonpreconditioned passage 2 adipose-derived stem cells. This randomized design allowed for a direct comparison of how metabolic stabilization influences the volume and quality of the resulting fusion mass, providing data on whether pre-treatment can compensate for the lack of a robust blood supply in the immediate postoperative period.

Quantifying Fusion Mass and Radiographic Outcomes

Eight weeks after the surgical procedure, the researchers utilized micro-computed tomography (micro-CT) imaging to quantify the volume and quality of the new bone formation. This radiographic technique allowed for a precise volumetric analysis of the fusion site, providing a clear metric for the success of the cellular graft. The study found that rats treated with dimethyloxalylglycine-preconditioned passage 2 adipose-derived stem cells developed significantly larger fusion masses, measuring 23.49 cubic millimeters compared to 15.39 cubic millimeters in the control group that received nonpreconditioned cells (P = .001). This substantial increase in bone volume suggests that metabolic priming enhances the ability of the implanted cells to contribute to the structural integrity of the fusion site within the early postoperative period. In addition to volumetric measurements, the researchers assessed the degree of bony union using standardized scoring systems for both radiographic and physical stability. Fusion outcomes on micro-CT were graded on a scale where 0 represented no fusion, 1 indicated unilateral fusion, and 2 signified bilateral fusion. The group receiving dimethyloxalylglycine-preconditioned cells exhibited a trend toward improved fusion outcomes, with a mean score of 1.16 compared to 0.50 in the nonpreconditioned group (P = .06). Physical stability was further evaluated through manual palpation, a clinical assessment where the motion of the spine is tested by hand and graded as 0 for nonfused, 1 for partial fusion, and 2 for complete fusion. The preconditioned group demonstrated a trend toward higher manual palpation scores, averaging 1.25 versus 0.66 in the control group (P > .05). While these secondary metrics did not reach the threshold for formal statistical significance, the consistent numerical improvement across both radiographic and physical assessments aligns with the significant gains observed in total fusion mass volume, suggesting a more robust clinical union.

Histological Evidence of Enhanced Bone Maturation

To evaluate the cellular architecture and quality of the newly formed bone, the researchers performed a histological evaluation (the microscopic analysis of tissue structure) to assess bone formation and tissue maturation. This histological evaluation revealed enhanced bone formation and tissue maturation in the preconditioned group compared to the control group receiving nonpreconditioned cells. Specifically, the researchers observed an increased osteoid matrix, which refers to the unmineralized organic portion of the bone tissue that serves as the scaffold for future mineralization. This finding suggests that the metabolic priming with dimethyloxalylglycine accelerated the early stages of bone deposition within the Vitoss scaffold. Detailed microscopic analysis also provided insights into the cellular activity and structural integrity of the fusion site. The preconditioned group exhibited larger osteoblast size, indicating a more robust metabolic state in these bone-forming cells. Despite the differences in bone volume and maturation, the study found a similarly extensive trabecular structure (the lattice-like network of cancellous bone that provides structural support) in both the preconditioned and control groups. Additionally, the researchers noted similar vascularization within the fusion site compared to controls, suggesting that the primary benefit of the preconditioning protocol was the enhancement of osteogenic activity rather than a significant increase in the density of new blood vessel formation. For the clinician, these findings indicate that preconditioning adipose-derived stem cells may improve the quality and volume of the fusion mass, potentially addressing the biological limitations of using autologous fat-derived cells in spinal arthrodesis and offering a pathway toward more reliable outcomes in patients with compromised healing environments.

References

1. Oehme D, Goldschlager T, Ghosh P, Rosenfeld JV, Jenkin G. Cell-Based Therapies Used to Treat Lumbar Degenerative Disc Disease: A Systematic Review of Animal Studies and Human Clinical Trials. Stem Cells International. 2015. doi:10.1155/2015/946031

2. Manolagas SC. Birth and Death of Bone Cells: Basic Regulatory Mechanisms and Implications for the Pathogenesis and Treatment of Osteoporosis*. Endocrine Reviews. 2000. doi:10.1210/edrv.21.2.0395

3. Han X, Liao R, Li X, et al. Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies. Signal Transduction and Targeted Therapy. 2025. doi:10.1038/s41392-025-02313-9

4. Xu G, Jin J, Fu Z, et al. Extracellular vesicle-based drug overview: research landscape, quality control and nonclinical evaluation strategies. Signal Transduction and Targeted Therapy. 2025. doi:10.1038/s41392-025-02312-w

5. Manchikanti L. An Update of Comprehensive Evidence-BasedGuidelines for Interventional Techniques inChronic Spinal Pain. Part I: Introduction andGeneral Considerations. Pain Physician. 2013. doi:10.36076/ppj.2013/16/s1